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Abstract
Background Ductal carcinoma in situ (DCIS) accounts for
approximately 20% of mammographically detected breast
cancers. Although DCIS is generally highly curable, some
women with DCIS will develop life-threatening invasive
breast cancer, but the determinants of progression to
infiltrating ductal cancer (IDC) are largely unknown.
Methods In the current study, we used multiplex ligation-
dependent probe amplification (MLPA), a multiplex PCR-
based test, to compare copy numbers of 21 breast cancer
related genes between laser-microdissectedDCIS and adjacent
IDC lesions in 39 patients. Genes included in this study were
ESR1, EGFR, FGFR1, ADAM9, IKBKB, PRDM14, MTDH,
MYC, CCND1, EMSY, CDH1, TRAF4, CPD,MED1, HER2,
CDC6, TOP2A, MAPT, BIRC5, CCNE1 and AURKA.
Results There were no significant differences in copy
number for the 21 genes between DCIS and adjacent IDC.
Low/intermediate-grade DCIS showed on average 6 gains/
amplifications versus 8 in high-grade DCIS (p=0.158).
Furthermore, alterations of AURKA and CCNE1 were
exclusively found in high-grade DCIS, and HER2, PRDM14
and EMSY amplification was more frequent in high-grade
DCIS than in low/intermediate-grade DCIS. In contrast, the
average number of alterations in low/intermediate and high
grade IDC was similar, and although EGFR alterations were
exclusively found in high grade IDC compared to low/
intermediate-grade IDC, there were generally fewer differ-
ences between low/intermediate-grade and high-grade IDC
than between low/intermediate-grade and high-grade DCIS.
Conclusion In conclusion, there were no significant differ-
ences in copy number for 21 breast cancer related genes
between DCIS and adjacent IDC, indicating that DCIS is
genetically as advanced as its invasive counterpart. However,
high grade DCIS showedmore copy number changes than low/
intermediate grade DCIS with specifically involved genes,
supporting a model in which different histological grades of
DCIS are associated with distinct genomic changes that
progress to IDC in different routes. These high grade DCIS
specific genes may be potential targets for treatment and/or
predict progression.
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1 Introduction
The most widely held concept regarding the development of
human breast cancer suggests that breast cancer progression is
a multistep process that manifests itself as a sequence of
pathologically defined stages with ductal carcinoma in situ
(DCIS) as final pre-invasive stage before progression to
invasive ductal carcinoma (IDC). Pathologically, DCIS is a
clonal epithelial proliferation that does not breech the basement
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membrane. IDC, on the other hand, is an abnormal proliferation
of breast epithelial cells that infiltrates through the basement
membrane into the surrounding stroma. The proportion of
patients diagnosed with DCIS, and with a mixture of DCIS and
IDC, is increasing as screening mammography becomes more
common. DCIS now accounts for approximately 20% of
mammographically detected breast cancers. Some women with
DCIS will develop life-threatening invasive breast cancer, but
the determinants of progression to IDC are largely unknown.
Therefore, all women with DCIS are generally treated fairly
aggressively with surgery and radiation. Biologic markers that
predict recurrence and/or progression to invasive cancer other
than traditional grading are thus warranted.
In the most popular model to explain the development of
IDC, low-grade DCIS tends to progress to low-grade IDC, and
high-grade DCIS tends to progress to high-grade IDC by
accumulation of fairly specific chromosomal and gene alter-
ations [5, 6, 23, 24, 37]. In the last decades, much progress
has been made in understanding the molecular and genetic
events that underlie the transition from preinvasive lesions
such as DCIS to IDC. The majority of molecular changes that
are observed in breast cancer seem to be already evident in
the DCIS stage [33, 36]. The search for biologic markers that
determine the transition from DCIS to IDC and thereby
predict the natural course of DCIS is, however, ongoing.
An impediment to our understanding of the biological
course of DCIS has been the limited extent of DCIS in
clinical specimens. Laser capture microdissection (LCM)
has, however, enabled the acquisition of pure populations
of target cells and has proven to be popular for use in
comparative genomic hybridization (CGH) [2] and loss of
heterozygosity (LOH) studies [4]. Still, the amount of DNA
that can be isolated in this way is often a limiting factor. In
contrast with other high throughput analysis methods,
multiplex ligation-dependent probe amplification (MLPA)
requires only small quantities of short DNA fragments,
which makes it very suitable for analysis of microdissected
paraffin embedded material [30]. In previous studies we
used MLPA to detect HER2 [28, 30] and TOP2A [31]
amplification and used its multiplex aspect to determine the
frequency of polysomy 17 in breast tumors [32].
In the current study, we applied MLPA to compare copy
number changes in 21 breast cancer related genes between
laser-microdissected DCIS and adjacent IDC lesions in 39
patients.
2 Materials and methods
2.1 Patient material
From paraffin embedded breast cancer resection specimens
of 39 patients, tissue blocks with DCIS and adjacent IDC
were selected by an experienced pathologist (PJvD) based
on the H&E stained sections. Grading of DCIS and
invasive cancer was done according to usual methods [16,
20]. DCIS and IDC lesions were subdivided into low/
intermediate-grade DCIS/IDC (DCIS n=19 and IDC n=15)
and high-grade DCIS/IDC (DCIS n=20 and IDC n=24).
Grading was done independently by two pathologists and
discordances were discussed until consensus was reached.
Anonymous use of redundant tissue for research purposes is
part of the standard treatment agreement with patients in
our hospital [46].
2.2 Laser microdissection
Laser microdissection was performed on 8 μm thick paraffin
sections (by comparing with a serial H&E stained slide where
IDC and DCIS were marked). For laser microdissection,
sections were baked at 56°C for 1 h, deparaffinized in xylene
for 10 min and rehydrated through graded alcohols (100%,
85% and 70% for 1 min each). After staining with haematox-
ylin for 5 s, slides were rinsed in water and dipped in eosin for
5 s. Finally, slides were dehydrated in 100% ethanol for 1 min
and air dried. At this point Liquid Cover Glass (PALM AG,
Bernried, Germany) was applied by aerosol to improve
morphology and to allow larger tissue areas to be laser
pressure-catapulted, and sections were air dried for at least
30 min. A PALM microdissection system with UV laser was
used to separate between 4 and 20 mm2 of DCIS or IDC from
their surrounding tissue. Subsequently, these areas were
catapulted by laser pressure catapulting into a cap of a
common microfuge tube moistened with a drop of mineral oil.
2.3 Multiplex ligation-dependent Probe Amplification (MLPA)
After laser microdissection, DNA was isolated by 1 h
incubation in proteinase K (10 mg/ml; Roche, Almere,
Netherlands) at 56°C followed by boiling for 10 min. This
DNA solution (50 μl) was, after centrifugation, used in the
MLPA analysis according the manufacturers’ instructions,
using the P078-B1 breast kit (MRC Holland, Amsterdam,
The Netherlands). Table 1 shows the contents of this kit and
includes chromosomal locations of all probes. All tests
were performed in duplicate on an ABI 9700 PCR machine
(Applied Biosystems, Foster City, CA, USA). PCR prod-
ucts were analyzed on an ABI310 capillary sequencer
(Applied Biosystems). Gene copy numbers were analyzed
using Genescan (Applied Biosystems) and Coffalyser
(version 7.0) software (MRC-Holland). Four negative
reference samples (normal breast) were taken along in each
MLPA run to normalize MLPA ratios. For genes with more
than one probe present in the kit, the mean of all the probe
peaks of this gene in duplicate was calculated. A mean value
below 0.7 was defined as loss, a value between 0.7 and 1.3
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was defined as normal, 1.3–2.0 as gain, and values >2.0 were
defined as (high level) amplification, as established previously
[7, 14].
2.4 Statistics
Statistics were performed using SPSS statistical software.
Copy number ratio differences for the 21 individual genes
between DCIS and adjacent IDC cases were compared with
paired T-test. In addition, we compared the mean copy
number ratio of each individual gene between the grouped
DCIS cases on the one hand and the IDC cases on the other.
Next, MLPA data were dichotomized as non-amplified vs.
gain/amplified (cut-off 1.3), and these gene dosage catego-
ries were compared between DCIS and IDC by McNemar’s
test. Furthermore, the mean MLPA copy number ratio
Table 1 Contents of the P078-B1 MLPA kit (MRC Holland, the
Netherlands). For each gene the chromosomal position, Mapview
distance from p-telomere, the number of probes present in the MLPA
kit, a description of the transcript protein and if possible a relevant
(breast cancer) reference is given
Gene Chr Mapview
position
# probes Transcript description Ref
ESR1 06q25 06-152.423838 2 Transcription factor [21]
06-152.457215
EGFR 07p11 07-055.191055 2 Receptor tyrosine kinase involved in signal transduction [39]
07-055.233957
FGFR1 08p12 08-038.391533 2 Receptor tyrosine kinase involved in signal transduction [11, 27]
08–038.434092
ADAM9 08p11 08-038.998319 1 Metalloproteinase associated with protein metabolism [11, 27]
IKBKB 08p11 08-042.292902 2 Serine/threonine kinase associated with signal transduction [11]
08-042.302676
PRDM14 08q13 08-071.130073 1 Transcription regulatory protein [35]
MTDH 08q22 08-098.742504 2 Metastasis promoting gene involved in chemoresistence [22]
08-098-788082
MYC 08q24 08-128.821796 3 Transcription factor involved in apoptosis and cell proliferation [42]
08-128.822001
08-128.822151
CCND1 11q13 11-069.167779 2 Cell cycle control protein involved in signal transduction [26]
11-069.175089
EMSY 11q13 11-075.902087 2 Transcription regulatory protein [26]
11-075.926543
CDH1 16q22 16-067.328716 2 Adhesion molecule associated with signal transduction [12]
16-067.404826
TRAF4 17q11 17-024.098403 1 Adaptor molecule involved in signal transduction, cell proliferation and apoptosis [10]
CPD 17q11 17-025.795018 1 Carboxypeptidase involved in protein metabolism -
MED1 17q12 17-034.840858 1 Transcription regulatory protein involved in signal transduction [48]




CDC6 17q21 17-035.699283 1 Cell cycle control protein involved in signal transduction [1]
TOP2A 17q21 17-035.812698 3 DNA topoisomerase protein involved in regulation of the topological status of DNA [38]
17-035.816651
17-035.818297
MAPT 17q21 17-041.423085 1 Structural protein involved in cell growth and/or maintainance –





CCNE1 19q12 19-035.000150 2 Cell cycle control protein involved in signal transduction [9, 25]
19-035.005214
AURKA 20q13 20-054.389980 1 Serine/threonine kinase involved in signal transduction [18, 43]
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including all 21 genes in all 39 patients was compared
between DCIS and IDC by T-test.
Hereafter, we compared different grades of DCIS and IDC.
First, we compared the mean copy number ratios between low/
intermediate and high grade DCIS, as well as between low/
intermediate grade and high grade IDC by T-test. Then, we
again dichotomized data and compared the mean number of
gains/amplifications between low/intermediate and high grade
DCIS, as well as between low/intermediate grade and high
grade IDC by T-test. P-values below 0.05 were considered
significant. Bonferroni correction was used to address the
problem of multiple comparisons. Finally, unsupervised
hierarchical clustering was applied with R as before [32].
3 Results
Supplementary Table 1 shows the raw copy number data.
Paired comparison of copy number ratios between DCIS and
adjacent invasive lesions did not yield significance for any of
the tested genes. Overall (unpaired) comparison of copy
number ratios between the grouped DCIS and invasive lesions
also did not yield significance for any of the tested genes.
Figure 1 shows the frequency of gain/amplification of 21
genes analyzed by MLPA in DCIS and adjacent IDC, using
dichotomized data. Although BIRC5 (survivin), TOP2A,
CCND1 and MED1 (PPARBP) gain/amplification seemed
to be more prevalent in DCIS than IDC, overall, there were
no significant differences between both components.
Chromosomes 8, 11 and 17 seem to show the most frequent
alterations in both breast lesions, the analyzed regions on
chromosomes 6, 7, 16, 19 and 20 to a lesser extent. We
found three genes showing frequent (>5%) loss: FGFR1,
CDH1 and MAPT, with also no significant differences
between DCIS and IDC.
Overall, there was no significant copy number difference
between DCIS (1.35 +/− 0.85) and IDC (1.34 +/− 0.88)
(p=0.604).
The mean copy number ratio was 1.29 +/− 0.71 in low/
intermediate-grade and 1.42 +/− 0.96 in high grade DCIS
(p=0.023), and 1.30 +/− 0.71 in low/intermediate-grade
and 1.36 +/− 0.97 in high grade IDC (p=0.308). The mean
number of gains/amplifications in the 21 analyzed genes
was 6 in low/intermediate-grade DCIS and 8 in high-grade
DCIS (p=0.158), and 6 in both low/intermediate-grade and
high grade IDC (p=0.903).
Also, as shown in Table 2, the pattern of alterations
differed between low/intermediate-grade and high-grade
DCIS, and in a much lesser extent between low/intermedi-
ate and high-grade IDC. Alterations of AURKA and
CCNE1 were exclusively found in high-grade DCIS, and
alterations of EGFR were exclusively found in high-grade
IDC. Figure 2 shows that gene copy numbers of HER2 (p=
0.013), MYC (p=0.009) and MTDH (not significant) were
higher in high-grade DCIS compared to low-intermediate
grade DCIS. Copy numbers of HER2 (p=0.037) were also
significantly higher in high-grade IDC compared to low/
intermediate grade IDC, as were those of TRAF4 (p=
0.088), but MAPT (p=0.108) and CCNE1 (p=0.070) gene
copy numbers seemed to be lower in high-grade IDC
compared to low-grade IDC.
Figure 3 shows the cluster analysis for all 39 DCIS/IDC
pairs according to their MLPA profiles based on 21 genes
and their grading. Twenty of the 39 pairs of DCIS/IDC
(51%) clustered closely together. Although not consistently,
most of the low/intermediate grade DCIS/IDC seemed to
belong to a different cluster than high-grade DCIS/IDC.
4 Discussion
This study aimed to investigate and compare copy number
changes within DCIS and adjacent IDC by MLPA. Overall,
there was no significant copy number difference between
DCIS and IDC, and the detected genetic alterations in

























































































































frequencies of 21 genes
analyzed by multiplex
ligation-dependent probe
amplification (MLPA) in DCIS
and adjacent IDC from 39 breast
cancer patients
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showed a high degree of shared changes within the two
components. This is consistent with previous studies [23]
and underlines that DCIS is genetically advanced, showing
a similar degree and position of chromosomal alterations as
invasive ductal cancer. Although copy number changes of
some genes such as BIRC5 seemed to be more prevalent in
DCIS than IDC, overall, no significant differences in gene
copy number between DCIS and adjacent IDC were found.
BIRC5 (survivin) has been described to be expressed in the
full spectrum of breast tissue from normal to IDC [45]. A 3-
fold higher cytoplasmic expression level has been described
in DCIS compared to IDC which has been correlated with
recurrence risk [3]. Our results also confirm previous
studies showing amplification (and overexpression) of
CCND1 in low-grade DCIS as well as in high-grade DCIS
[8, 17, 44]. According to the author’s current knowledge,
DCIS IDC
Low/intermediate grade High-grade Low/intermediate grade High-grade
ESR1 16 15 13 25
EGFR 5 10 0 4
FGFR1 32 55 27 38
ADAM9 58 45 67 50
IKBKB 37 40 47 38
PRDM14 11 40 33 29
MTDH 53 65 47 83
MYC 42 65 47 63
CCND1 53 40 27 42
EMSY 11 20 33 33
CDH1 21 15 7 25
TRAF4 42 65 33 58
CPD 21 40 53 33
MED1 42 50 40 29
HER2 21 65 33 33
CDC6 42 55 47 42
TOP2A 47 45 47 29
MAPT 16 35 7 21
BIRC5 26 30 13 13
CCNE1 0 15 7 4
AURKA 0 25 7 8




high-grade DCIS and adjacent
IDC present in 39 breast
tumor samples
DCIS ductal carcinoma
in situ, IDC invasive ductal
carinoma
Fig. 2 MLPA copy number ratio’s of HER2, MYC and MTDH in low/intermediate-grade DCIS (DCIS low, n=19) and high-grade DCIS (DCIS
high, n=20) of 39 breast tumors
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many of the other genes investigated in this study, including
MED1, FGFR1, IKBKB, PRDM14, MTDH, CPD, CCNE1
and AURKA have not been investigated for their copy
number alterations in DCIS and adjacent IDC until now. A
previous study has investigated copy number alterations of
all genes in this study in a large group of IDC using the
same MLPA kit and showed similar copy number alteration
frequencies in literature [29].
The number as well as the pattern of alterations differed
between low/intermediate and high grade DCIS, supporting
a model in which different histological grades of DCIS are
associated with distinct genomic changes [13]. These genes
showing alterations may be potential targets for treatment
and/or markers of prognosis. HER2 showed more frequent
gain/amplification in high grade DCIS (65%) than in low-
intermediate (21%), which is consistent with previous
studies showing more frequent gain of 17q and higher
HER2 expression levels in high-grade DCIS [13, 23, 47].
Poorly differentiated DCIS has also been associated with
frequent loss of 8p, which is consistent with our data since
FGFR1 on 8p11 showed no loss in low/intermediate grade
DCIS compared to 25% loss in high-grade DCIS. MYC
amplifications were found in IDC as well as in DCIS
without any significant differences in frequency between
both components. This is inconsistent with a FISH study
that could not demonstrate MYC amplifications in DCIS
adjacent to FISH-amplified IDC [41]. In this study, the
MLPA ratio was higher in IDC compared to DCIS in 56%
of cases, but in most cases (16/22) this did not lead to a
different amplification status (gain versus normal, no
differences were found in the 13% high level amplifica-
tions) between both lesions. Furthermore, MYC amplifica-
tions seem to be more prevalent in high-grade DCIS lesions
(65%) than in low/intermediate-grade lesions (42%), which
is consistent with previous studies [8].
Some alterations (CCNE1 19q12 and AURKA 20q13)
were exclusively found in high-grade DCIS. However, at
this moment, no single gene has been identified that
differentiates between different types of DCIS. Perhaps
the indicated genes could be candidates. Given the small
size of the present study group, these data have to be
confirmed in larger studies.
Table 2 and statistical analysis show that, overall, the
differences between low/intermediate and high grade DCIS
seemed to be bigger than between low/intermediate and
high-grade IDC. For example, whereas HER2, EMSY and
PRDM14 gains/amplifications were as frequent in low/
intermediate grade IDC as in high-grade IDC, the amplifi-
cation of these genes seemed to be less frequent in low/
intermediate-grade DCIS than in high-grade DCIS. These
Fig. 3 Cluster analysis of 21 genes in low/intermediate and high grade DCIS and adjacent IDC (Grade: dark brown: grade 1, light brown: grade
2, blue: grade 3)
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differences may be prognostically important, or may turn
out to be important variables in the choice of therapy.
Cluster analysis showed a trend towards clustering by
grade, but several low/intermediate-grade DCIS/IDC clus-
tered together with high-grade DCIS/IDC, indicating that low-
grade DCIS can be genetically as advanced as high-grade
DCIS. Twenty of the 39 DCIS-IDC pairs clustered closely
together, indicating a similar genetic profile of both compo-
nents. This implies that, at least for the studied genes, DCIS is
genetically as advanced as its invasive counterpart. Neverthe-
less, although no significant differences were observed
between DCIS and IDC, not all DCIS/IDC pairs clustered
together. It is possible that a larger gene set spread over more
different chromosomal locations could better discriminate the
samples. For example, Hannemann et al. identified a gene
expression classifier of 35 genes which differed between
DCIS and invasive breast cancer [19]. This same group also
identified a 43-gene classifier to separate well- and poorly
differentiated DCIS samples. Unfortunately, the genes
identified in that study did not overlap with the genes
investigated using the MLPA P078-B1 kit in our study,
except for ESR1. This gene was identified by Hannemann et
al. as a discriminator between well- and poorly differentiated
DCIS. However, this gene did not show significant differ-
ences in our study (15% and 16% alterations). This could be
explained by the fact that Hannemann et al. looked at the
expression of ESR1 in contrast to the copy number. Several
studies have indicated that there is no absolute relationship
between ESR1 gain or amplification and mRNA and protein
expression in breast cancer [34, 40].
In conclusion, this study showed that MLPA is suited to
simultaneously detect amplification or loss of many potential
prognostic or predictive genes in breast cancer. We found no
significant differences between DCIS and adjacent IDC, but
the number as well as the pattern of alterations differed
between high- and low/intermediate-grade DCIS. Overall,
the differences between low/intermediate and high-grade
DCIS seemed to be bigger than between low/intermediate and
high-grade IDC.
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